- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05423340
Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems (CRoFT)
June 21, 2023 updated by: Roswell Park Cancer Institute
A Randomized, Parallel-group Open-label Trial of ENDS Users Switching From Flavors of Potentially High-toxicity Profile to Flavors of Potentially Low-toxicity Profile (CRoFT_3.2)
This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
216
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maciej Goniewicz, PhD
- Phone Number: 716-845-2300
- Email: Maciej.Goniewicz@roswellpark.org
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14206
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
Contact:
- Maciej Goniewicz, MD
- Phone Number: 800-767-9355
- Email: askroswell@roswellpark.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- ENDS users as determined by: (a) using banned flavored ENDS with nicotine such as fruit, candy, dessert flavors, and/or any product that indicates such flavors (b) using ENDS daily, regularly for the past 6 months (self-reported).
- No smoking tobacco or using smokeless tobacco for the past 6 months.
- Subjects should be free of acute respiratory illness within the proceeding 30 days prior to recruitment (self-reported).
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
- After receiving information regarding the NYS flavor ban individuals must not want to quit vaping or stop using their flavored product for the next 90 days.
Exclusion Criteria:
- Individuals with health conditions and therapies that may affect immune responses and levels of inflammatory markers, including allergic rhinitis, aspirin/NSAID therapy, asthma, immunodeficiency (HIV or other), Guillain-Barre Syndrome, COPD, or fever/respiratory illness within 30 days prior to entry into study (self-reported).
- Pregnant or nursing female participants (self-reported on telephone screener, pregnancy test on Visit#1)
- Unable to communicate in English.
- Unable or unwilling to follow protocol requirements.
- Self-report having active, untreated medical/psychiatric conditions.
- History of serious side effects from nicotine or from any nicotine replacement therapies.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Vulnerable populations, such as cognitively impaired adults, individuals who are not yet adults, pregnant women, and prisoners.
- Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.
- After receiving information about the NYS flavor ban, participants who report that they are thinking about quitting or stop using their flavor within the next 90 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Use Own Brand of Flavored Product
Participants will use their current flavor of e cigarettes for 90 days
|
Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
|
Experimental: Use Provided Tobacco Flavor
Participants will use a new assigned flavor for 90 days
|
Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
|
Active Comparator: Vaping Abstinence - use "Tobacco Free" Nicotine Pouches
Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.
|
participants will use tobacco free oral nicotine pouches
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk biomarkers of inflammation and oxidative stress as measured by ELISA
Time Frame: Up to 90 days
|
Oxidative stress and inflammation in plasma using ELISA .
A quantitative measure of expression (units:pg/mg) will be produced.
|
Up to 90 days
|
Respiratory tract inflammation activity
Time Frame: Up to 90 days
|
Exhaled Nitric Oxide (FeNo)l be measured in participants' breath using a FDA cleared monitor NIOX VERO (Aerocrine) according to ATS guidelines.
FeNO has been used to monitor airway inflammation to account for persistent and/or high allergen exposure as a factor associated with higher levels of FeNO
|
Up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of recent flavored product use
Time Frame: UP to 90 days
|
Assessed using the PhenX Toolkit which tracks tobacco use and asks subjects to retrospectively estimate product use,
|
UP to 90 days
|
Flavor Preference questionnaire
Time Frame: Up to 90 days
|
Personal flavor questionnaire to determine flavor preference when using ENDS.
|
Up to 90 days
|
Frequency of flavored product use
Time Frame: Up to 90 days
|
Questions from Wave 1 Adult PATH Survey to measure use and regularity of use flavored products
|
Up to 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Maciej Goniewicz, PhD, Roswell Park
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 12, 2022
Primary Completion (Estimated)
June 12, 2025
Study Completion (Estimated)
June 12, 2025
Study Registration Dates
First Submitted
June 3, 2022
First Submitted That Met QC Criteria
June 13, 2022
First Posted (Actual)
June 21, 2022
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 21, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I 2588022
- U54CA228110 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Electronic Cigarette Use
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | E-Cig UseUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA)Completed
-
University of OklahomaNational Institute on Drug Abuse (NIDA); University of Wisconsin, Madison; University... and other collaboratorsRecruiting
-
Virginia Commonwealth UniversityU.S. Department of JusticeRecruitingElectronic Cigarette UseUnited States
-
Eastern Virginia Medical SchoolNational Institute on Drug Abuse (NIDA)Terminated
Clinical Trials on E-cigarette Flavor
-
Virginia Polytechnic Institute and State UniversityNational Cancer Institute (NCI); University of MinnesotaCompletedTobacco Use DisorderUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Food and Drug Administration (FDA)Terminated
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruitingCigarette Smoking | Sex Differences | Nicotine Addiction | E-Cig Use
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaFondazione Salvatore MaugeriCompleted
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Roswell Park Cancer InstituteCompleted
-
University of OklahomaCompletedSmoking CessationUnited States
-
University of California, Los AngelesTobacco Related Disease Research ProgramCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA)RecruitingSmoking | Nicotine Dependence | Smoking BehaviorsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); University...CompletedNicotine Dependence | Smoking, Tobacco | Smoking, Cigarette | Exposure to Toxic AgentUnited States
-
GWT-TUD GmbHTerminated